Star Scientific, Inc. (Nasdaq: CIGX) announced that on Friday, February 19 the company filed an application with the Food & Drug Administration for approval to market Ariva-BDL™ as a "modified risk" tobacco product under the Family Smoking Prevention and Tobacco Control Act of 2009. This submission is the first such application to be filed with the Tobacco Products Center of the FDA, which has been established to oversee all aspects of tobacco regulation outlined in the 2009 Act.
Ariva-BDL™, a dissolvable tobacco lozenge with wintergreen flavoring, is made with flue-cured tobacco that contains levels of tobacco-specific nitrosamines (TSNAs) that are below detectable limits ("BDL") by most current standards of measure. TSNAs have been identified in scientific literature since the early 1950s as one of the most deadly and abundant groups of carcinogens in tobacco and its smoke. Achieving this reduction, known within Star as "ZNT" (zero-nitrosamine tobacco) was accomplished by new work on the StarCured® tobacco curing technology that originally was developed in the 1990s. This innovation is the subject of a patent application filed in December 2008. A recent article by Rickert et al. (Regulatory Toxicology and Pharmacology 2009;53(2):121-33) reported total TSNA levels in currently marketed popular moist snuff and "pouch" tobacco products that ranged from 8,814 - 14,557 parts per billion. This range is 1000 times greater than the levels measured in Ariva-BDL™, as outlined in the company's submission.
Star Scientific believes these developments are of great significance in light of the reality that 43 million Americans -- roughly half of them women -- smoke each day. More than half of this population is looking for an acceptable alternative to cigarettes. Cigarette revenues in the United States currently total $75 - $80 billion, according to the Wall Street Journal. While a number of male smokers in the US now use traditional smokeless tobacco as an alternative to smoking, female smokers do not accept the unpleasant aesthetics of using moist snuff. As a completely dissolvable lozenge, Ariva-BDL™ would offer a useful alternative -- with greatly reduced toxin levels -- to adult smokers of both genders.
Star Scientific originally introduced dissolvable smokeless tobacco to the marketplace almost ten years ago when it launched Ariva® in 2001, and Stonewall Hard Snuff® in 2003. Both products are pieces of powdered and compressed StarCured® tobacco that dissolve completely in the mouth and leave no residue. Ariva®, launched in 2001, was developed for adult dependent smokers who cannot or choose not to smoke. Stonewall Hard Snuff®, launched in mid-2003, is an alternative for adults who use traditional smokeless tobacco products or who identify themselves as "heavy smokers". Over the past nine years the company has learned that Ariva® customers range in age from 30 - 70, and more than half of whom are women. Stonewall Hard Snuff® purchasers range in age from 25 - 65. Customers who are looking for an alternative to moist snuff are largely male, while roughly 30 - 40% of those who purchase the products as an alternative to "heavy" daily cigarette smoking are female. According to callers to the product consumer call center, the majority of purchasers are concerned about continued smoking. Both Ariva and Stonewall are available with wintergreen flavoring, which have been the blend most often purchased by Star's customers.